By Daniella Parra Promontory Therapeutics, a clinical stage pharmaceutical company focused on oncology, said it treated its first four patients in France for late-stage metastatic castration-resistant prostate cancer (mCRPC). The study is being led by oncologist Dr. Karim Fizazi at Gustave Roussy and the Military Hospital (HIA) Bégin in Paris, the company said. The trial […]